Bladder CancerNCT06046469
Validity of Computed Tomography Versus Magnetic Resonance Imaging in Predicting Muscular Invasion of Bladder Cancer
A study testing CT with contrast, MRI pelvis and TURBT in people with Bladder Cancer, run by Menoufia University at 1 site in Egypt.
Trial summary
The aim of this work is to compare validity between CT and MRI in detecting muscular invasion in Patients with bladder cancer. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Bladder Cancer
- What is being tested?
- CT with contrast, MRI pelvis and TURBT
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 55 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Sep 2022to 1 Mar 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- patients with urinary bladder mass
Who cannot join
- bleeding tendency ,patients had chemo , radiotherapy
Trial locations and contacts
1 site in 1 country.
Egypt1 site, 1 recruiting
- Recruiting
Faculty of Medicine Menofia University
Shibīn al Kawm, Menofia, 32511
AHMED F AHMED, professor, 2224886 ext. 2048, ahmed.elkased@med.menofia.edu.eg
About this study
The aim of this work is to compare validity between CT and MRI in detecting muscular invasion in Patients with bladder cancer.
- Conditions
- Bladder Cancer
- Being tested
- CT with contrast, MRI pelvis, TURBT
- Medical subject headings
- Urinary Bladder Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CT with contrastDiagnostic test
CT abdomen and pelvis with IV contrast
MRI pelvisDiagnostic test
MRI pelvis with contrast
TURBTProcedure or surgery
transurethral resection of bladder tumor
| Study group | Role | What they receive |
|---|---|---|
| CT group | Active comparator | this group of patient is doing CT abdomen and plevis with IV contrast then they undergo TURBT and compare the radiological staging to histopathological staging. Receives: Diagnostic Test: CT with contrast; Procedure: TURBT |
| MRI group | Active comparator | this group of patient is doing MRI pelvis with contrast then they undergo TURBT and compare the radiological staging to histopathological staging. Receives: Diagnostic Test: MRI pelvis; Procedure: TURBT |
What is being measured
The primary outcome is the main question the study is designed to answer.
which is better to detect muscular invasion in bladder cancer CT vs MRI
the radiological staging of CT and MRI compared to histopathological staging
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2023
- Study start1 Sep 2022
- Primary completion1 Dec 2023 (estimated)
- Study completion1 Mar 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bladder CancerStudies of the same condition, open and under way.
- More trials run by Menoufia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 55 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Menoufia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Abdulrhman Ismail Abdulrhman Elkhouly, Menoufia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06046469
- Sponsor's protocol ID
- CT vs MRI in bladder cancer
- Status last verified
- Sep 2023
- First submitted
- 14 Sep 2023
- Last updated
- 21 Sep 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validity of Computed Tomography Versus Magnetic Resonance Imaging in Predicting Muscular Invasion of Bladder Cancer
- ClinicalTrials.gov ID
- NCT06046469
- Acronym / sponsor ID
- CT vs MRI in bladder cancer
- Conditions
- Bladder Cancer
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 55 participants (estimated)
- Lead sponsor
- Menoufia UniversityUniversity, hospital or other
- Study start
- 1 Sep 2022 (actual)
- Primary completion
- 1 Dec 2023 (estimated)
- Study completion
- 1 Mar 2024 (estimated)
- First posted
- 21 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this work is to compare validity between CT and MRI in detecting muscular invasion in Patients with bladder cancer.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CT group | Active comparator | Diagnostic Test: CT with contrast, Procedure: TURBTthis group of patient is doing CT abdomen and plevis with IV contrast then they undergo TURBT and compare the radiological staging to histopathological staging. |
| MRI group | Active comparator | Diagnostic Test: MRI pelvis, Procedure: TURBTthis group of patient is doing MRI pelvis with contrast then they undergo TURBT and compare the radiological staging to histopathological staging. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- patients with urinary bladder mass
Key exclusion criteria (1 listed)
- bleeding tendency ,patients had chemo , radiotherapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CT with contrastCT abdomen and pelvis with IV contrast | Diagnostic test | CT group |
| MRI pelvisMRI pelvis with contrast | Diagnostic test | MRI group |
| TURBTtransurethral resection of bladder tumor | Procedure or surgery | CT group, MRI group |
Primary outcome
which is better to detect muscular invasion in bladder cancer CT vs MRI
Time frame: 1 month
the radiological staging of CT and MRI compared to histopathological staging
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2023.
- Individual participant dataSharing planned: No
Related trials for Bladder Cancer
RecruitingPhase 2/3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
RecruitingPhase 3
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
Bladder Cancer
Active, not recruitingPhase 2/3
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Biliary Tract Cancer, Cholangiocarcinoma
Recruiting
Effect of Cyclic Sighing Breathing Exercise on CRBD, Pain, and Sleep Quality in Patients Undergoing TUR
Transurethral Resection of Bladder Tumor, Transurethral Resection of the Prostate (TURP)
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CT with contrast, MRI pelvis and TURBT in people with Bladder Cancer, run by Menoufia University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact ABDULRHMAN IS ELKHOULY, bachelor (01010054452 ext. 02, abdo.elkholy20@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
which is better to detect muscular invasion in bladder cancer CT vs MRI (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2023.